By Staff Reporter Lima, Peru – The Population Council, an international nonprofit research organization, announced today at HIVR4P 2024, the 5th HIV Research for Prevention Conference, the results of a phase I open-label randomized crossover relative bioavailability trial (IPM 054). The trial found that a 3-month dapivirine vaginal ring delivers the active antiretroviral drug, dapivirine, at higher levels than the 1-month dapivirine vaginal ring. The trial, conducted among 124 women in South Africa, suggests that the longer-acting ring will be as effective as the 1-month ring, offering a more cost…
Read More3-Month Dapivirine Vaginal Ring for HIV Prevention Demonstrates Superior Drug Release Compared to 1-Month Ring
